Optimi Health Completes On-Premises Analytics Expansion

VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed the planned expansion of the on-site analytical laboratory of its facility of Princeton, British Columbia.

The on-site lab is purpose-built inside one of Optimi’s state-of-the-art 10,000 square foot EU-GMP compliant indoor cultivation facilities dedicated to the cultivation of safe, high quality psychedelic and functional mushrooms. Optimi’s Chief Scientific Officer, Justin Kirkland, will oversee the company’s analytical operations.

“Our analytical lab will prove a completely consistent dosage on natural psilocybin products that will meet strict FDA and EU-GMP standards,” Kirkland said. “We will measure and ensure the integrity, ongoing stability and accuracy of all our natural and psychedelic psilocybin formulations and finalize our standard operating procedures to meet Health Canada and international standards.”

The newly expanded analytical laboratory will operate as a division of Optimi Labs Inc., a wholly owned subsidiary of Optimi Health, and is designed for both formulation research and proprietary extraction methods. company and for use by customers, partners and approved companies to conduct molecular discovery investigations with restricted psychedelic compounds.

Optimi CEO Bill Ciprick says expanding the lab is a critical part of the company’s planned revenue strategy.

“While Optimi’s primary goal remains the cultivation of a safe and scalable supply of EU-GMP natural psilocybin, we realize that operationalizing a future for psychedelic science in which the greatest number of patients allowed gaining access to these drugs requires a more robust research infrastructure than currently exists, especially in light of the current levels of interest and demand from so many entities across space. This lab is our contribution to that future.” , Ciprick added.

Along with its primary objective of becoming a leading ingredient supplier of naturally grown psilocybin mushrooms and extracts, the Company intends to expand its efforts with third parties requiring additional facilities and analytical support in the processes. drug discovery as well as single and multi-site clinical trials.

In a press release issued by the company on Monday, May 9, Optimi applauded Health Canada’s May 6 advisory to stakeholders highlighting “the importance of drug quality and good manufacturing practices (GMP)” regarding “the proposed use of psilocybin mushrooms in clinical trials, or as a medicine accessible through the Special Access Program (SAP).

“We commend Health Canada for making quality assurance and GMP compliance a necessity in all clinical and observational protocols going forward,” Ciprick said. “With our analytical capability now in place, we look forward to helping industry suppliers validate their product and meet the demand for GMP-grade psilocybin.”


Optimi Health is a homegrown Canadian success story that produces and supplies EU-GMP grade natural psilocybin and functional mushrooms focusing on the health and wellness markets. Built with the goal of producing scalable natural mushroom formulations for transformational human experiences, the company’s goal is to be the trusted and compassionate premier provider of natural and safe GMP grade psilocybin throughout the world. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products at its two facilities totaling 20,000 square feet in Princeton, in British Columbia.

In order to fully investigate the science of mushrooms, the company has received a research exemption under the Food and Drug Regulations (FDR) from Health Canada for the use of psilocybin and psilocin for scientific purposes through its wholly-owned subsidiary Optimi Labs Inc. Optimi has also obtained a distributor’s license under the Narcotic Control Regulations of Canada governing the possession, distribution, sale, laboratory analysis, and research and development of psilocybin formulations and psilocin. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and regulations to ensure safe and superior Canadian mushroom production.


Investor Relations
Email: [email protected]
Telephone: +1 (902) 880 6121
Web: https://optimihealth.ca


This press release contains forward-looking statements and forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”) that relate to Optimi’s current expectations and beliefs about future events. Any statement that expresses or implies discussions of expectations, beliefs, plans, goals, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as ” will likely result”, “are expected”, “expects”, “will continue”, “is planned”, “anticipates”, “believes”, “estimates”, “intends”, “plans”, “plans”, “projection”, “strategy”, “target” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results will differ materially from those expressed in such forward-looking statements. No assurance can be given that such expectations will prove to be correct and undue reliance should not be placed on the forward-looking statements included in this press release. Such statements are only made as as of the date of this press release. In particular, and without limitation, this press release contains forward-looking statements relating to the activities proposed to be conducted under the Company’s reseller license and related activities relating to plans, direction and objectives. psilocybin and psilocin and Optimi.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially. of those disclosed or implied by such statements. forward-looking statements. These risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under the headings “Forward-Looking Statements” and “Risk Factors” in the Company’s Annual Information Form. Company dated January 12, 2022. , and other continuous disclosure documents available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. New factors appear from time to time, and it is not possible for Optimi to predict them all or assess the impact of each of these factors or the extent to which any one factor, or combination of factors, may cause results significantly different from those contained. in any forward-looking statements.

All forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Comments are closed.